Supreme Court Blocks Restrictions on Abortion Pill Access via Mail and Telehealth

The U.S. Supreme Court has issued a temporary hold on a federal appeals court’s decision that threatened to end telemedicine and mail-order access to abortion pills nationwide. The one-paragraph order, released late Thursday, ensures that mifepristone—the most commonly used abortion pill—can still be prescribed via telehealth and mailed to patients, even in states with strict abortion bans.

This development follows weeks of legal turmoil after the far-right Fifth Circuit Court of Appeals suspended FDA rules on May 1, 2024, which had allowed online dispensing of mifepristone under Biden-era policies. The Supreme Court’s intervention comes after a 10-day stay issued by Justice Samuel Alito, who had temporarily paused the Fifth Circuit’s order while the Court weighed its next steps.

Background: Rising Abortion Access Despite State Bans

Since the 2022 Dobbs v. Jackson Women’s Health Organization decision overturned Roe v. Wade, more than a dozen Republican-led states have enacted near-total abortion bans. Paradoxically, the total number of abortions in the U.S. has risen over the past four years, including in states where abortion is nearly illegal. Abortion opponents attribute this increase to policy changes under the Obama and Biden administrations, particularly a 2023 FDA rule eliminating the requirement for in-person prescribing and dispensing of mifepristone.

Currently, nearly two-thirds of all abortions in the U.S. involve medication abortion, with about 30% conducted via telemedicine.

Legal Battle Over Mifepristone Access

Louisiana filed a lawsuit against the FDA in fall 2023, arguing that the 2023 rule change was politically motivated rather than scientifically justified. The state claimed the policy undermined the intent of Dobbs by allowing abortion providers to circumvent state-level restrictions. On Thursday, Justice Alito—who authored the Dobbs decision—joined Justice Clarence Thomas in dissenting against the Supreme Court’s decision to pause the Fifth Circuit’s order.

Alito criticized the majority’s reasoning as “unreasoned” and “remarkable,” while condemning blue-state “shield laws” that protect telehealth providers serving patients in restricted states. He described these laws as a “scheme” to undermine Dobbs and accused states like Louisiana—home to some of the nation’s strictest abortion laws—of being undermined by out-of-state providers.

In his dissent, Justice Thomas invoked the Comstock Act, a 19th-century federal law that prohibits mailing “any drug… for producing abortion.” Thomas suggested that mifepristone manufacturers Danco Laboratories and GenBioPro Inc. could be engaged in a “criminal enterprise” under this law. He argued that enforcing the Comstock Act would effectively impose a national abortion ban.

The Supreme Court’s order does not resolve the underlying legal dispute but temporarily preserves the status quo while the case proceeds. The Court’s decision reflects the ongoing national debate over abortion access, medication abortion, and the balance of federal versus state authority in regulating reproductive healthcare.